vTv Therapeutics (NASDAQ:VTVT) Upgraded by Lifesci Capital to “Strong-Buy” Rating

Lifesci Capital upgraded shares of vTv Therapeutics (NASDAQ:VTVT) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

Several other analysts also recently weighed in on VTVT. BTIG Research boosted their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. HC Wainwright cut their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Zacks Research downgraded shares of vTv Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Finally, Rodman & Renshaw assumed coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Trading Up 0.2%

Shares of vTv Therapeutics stock opened at $33.47 on Wednesday. vTv Therapeutics has a 12-month low of $18.00 and a 12-month high of $44.00. The firm has a market capitalization of $131.87 million, a price-to-earnings ratio of -31.58 and a beta of 0.29. The firm’s 50 day simple moving average is $33.05 and its two-hundred day simple moving average is $34.57.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, sell-side analysts predict that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the 4th quarter worth about $221,000. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the fourth quarter valued at approximately $731,000. Finally, Geode Capital Management LLC grew its holdings in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the period. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.